logowsbdaily | Thu, 01 Dec 2022 23:15:06 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Veru Inc.
(VERU)

Veru Inc.
2916 North Miami Avenue
Suite 1000
Miami, FL 33127
United States
Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company's drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clini... Read More

Summary & Charts

Price$ 14.44+4.09 (+39.51%)
Day's Range$ 11.80 - 15.90 
Previous Close$ 10.35
Market Cap$ 1.16B USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqCM
IndustryBiotechnology
SectorHealthcare
Volume55.06M
Avg. Volume (20 day)4.81M
Rel. Volume (20 day)11.44
Rel. Volume (3 month)7.85
RatingBNeutral
DCFN/AStrong Buy
Debt/Equity37.40 %Neutral
ROE-34.02 %Sell
ROA-30.05 %Sell
P/E-24.35 %Strong Sell
P/B9.80 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Nov 07, 2022$ 12.00$ 15.90$ 11.80$ 14.44+4.0955,064,13211.447.855
Nov 04, 2022$ 11.50$ 11.58$ 10.29$ 10.35-0.933,848,7991.790.62
Nov 03, 2022$ 11.33$ 11.94$ 11.23$ 11.28-0.181,752,3290.850.28
Nov 02, 2022$ 12.59$ 12.60$ 11.43$ 11.46-0.952,689,7461.290.43
Nov 01, 2022$ 12.51$ 12.93$ 12.28$ 12.41+0.171,982,3590.960.32
Oct 31, 2022$ 12.13$ 12.81$ 12.07$ 12.24+0.032,720,0321.260.43
Oct 28, 2022$ 12.34$ 12.98$ 12.08$ 12.21-0.032,013,1580.910.32
Oct 27, 2022$ 12.17$ 12.52$ 12.08$ 12.24+0.151,292,3280.560.201
Oct 26, 2022$ 11.67$ 12.85$ 11.63$ 12.09+0.462,584,6241.050.39
Oct 25, 2022$ 10.89$ 11.72$ 10.86$ 11.63+0.742,011,2330.830.291
Oct 24, 2022$ 11.25$ 11.25$ 10.56$ 10.89-0.292,097,7030.840.29
Oct 21, 2022$ 11.09$ 11.24$ 10.89$ 11.18+0.011,686,3800.660.23
Oct 20, 2022$ 11.01$ 11.57$ 10.91$ 11.17+0.051,155,3160.420.16
Oct 19, 2022$ 11.64$ 12.04$ 11.00$ 11.12-0.822,107,5430.740.29
Oct 18, 2022$ 11.66$ 12.60$ 11.59$ 11.94+0.473,176,4311.020.43
Oct 17, 2022$ 11.10$ 11.94$ 11.05$ 11.47+0.612,511,1100.770.33
Oct 14, 2022$ 11.48$ 11.72$ 10.79$ 10.86-0.541,239,8370.320.16
Oct 13, 2022$ 10.91$ 11.69$ 10.25$ 11.40+0.452,462,5630.620.32
Oct 12, 2022$ 11.09$ 11.17$ 10.46$ 10.95-0.201,745,6080.440.23
Oct 11, 2022$ 10.61$ 11.40$ 10.48$ 11.15+0.542,095,8030.520.27

News

The latest news about Veru Inc. (VERU).

InvestorPlace | 2022-11-07 14:30:16
Pharmaceutical firm Veru (NASDAQ: VERU ) kicked off the first complete week of November with a bang as it delivered overall positive results regarding its Covid-19 therapeutic sabizabulin. Targeting the treatment of Covid-19 for hospitalized patients at high risk of acute respiratory distress syndrome (ARDS), sabizabulin demonstrated effectiveness at reducing the death rate in a late-stage trial.
Investors Business Daily | 2022-11-07 13:44:34
Veru stock skyrocketed Monday after the Food and Drug Administration posted a mixed review of its repurposed cancer drug for Covid treatment. The post Medical Leader Veru Catapults As FDA Preps To Discuss Cancer Drug For Covid appeared first on Investor's Business Daily.
GlobeNewsWire | 2022-10-13 08:30:00
MIAMI, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that data from the Phase 3 trial of sabizabulin for hospitalized moderate to severe COVID-19 patients who required supplemental oxygen has been accepted as a late-breaker oral presentation at the upcoming IDWeek (Infectious Disease Week) 2022 taking place October 19-23, 2022, in Washington, D.C.
The Motley Fool | 2022-10-09 09:45:00
Both companies have revenue rolling in today, and they both expect loads more in the near term.
InvestorPlace | 2022-09-26 06:45:14
Before jumping directly into momentum stocks worth buying now, it's important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement of a stock or sector.
Seeking Alpha | 2022-09-08 12:49:49
Today, we put Veru Inc. in the spotlight for the first time. The stock fell over 20% trading Wednesday after the FDA stated it would require an AdComm Panel for the company's COVID-19 therapy sabizabulin prior to approval.
GlobeNewsWire | 2022-09-07 13:45:00
—Advisory Committee Meeting Scheduled for October 06, 2022— —Advisory Committee Meeting Scheduled for October 06, 2022—

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-11-30BMO-0.3----12M----
2022-08-11BMO-0.16-0.2875%------
2022-05-12BMO-0.15-0.1820%------
2022-02-09BMO-0.11-0.0827.28%13M14M8.73%
2021-12-02BMO-0.09-0.0544.45%13M16M20.35%
2021-08-12BMO-0.06-0.0350%14M18M25.21%
2021-05-12BMO-0.04-0.04--13M13M--
2021-02-10BMO-0.060.23483.34%77M15M-80.96%

Top Discussions

These are the top discussions over the last 24-hours that mention the VERU stock ticker symbol.


Unusual Option Activity

Option contracts that are trading at a significantly higher volume relative to the contract's open interest. These might provide some insight into what "smart money" is doing with large volume orders.

TypeStrikeExp DateDTEBidAskLastVolumeOpen InterestVol/OIIV
CALL$ 7.0011/10/220$ 0.30$ 0.40$ 0.352,40514716.362.50%
CALL$ 7.5011/10/220$ 0.15$ 0.20$ 0.171,4582754.002.53%
CALL$ 10.0011/10/220$ 0.00$ 0.05$ 0.052531961.293.88%
CALL$ 10.5011/10/220$ 0.00$ 0.05$ 0.0472391.854.25%
CALL$ 11.0011/10/220$ 0.00$ 0.05$ 0.092681581.704.63%
CALL$ 11.5011/10/220$ 0.00$ 0.05$ 0.054232851.485.00%
PUT$ 6.0011/10/220$ 0.05$ 0.10$ 0.092,0111,1611.732.78%
PUT$ 6.5011/10/220$ 0.05$ 0.25$ 0.176661295.162.38%
CALL$ 6.0011/17/226$ 1.20$ 1.45$ 1.4534172.001.95%
CALL$ 7.0011/17/226$ 0.70$ 0.85$ 0.771,3375723.461.92%
CALL$ 8.0011/17/226$ 0.40$ 0.45$ 0.442,8001,0502.671.91%
CALL$ 8.5011/17/226$ 0.35$ 0.40$ 0.39136403.402.09%
PUT$ 5.5011/17/226$ 0.15$ 0.30$ 0.2579145.642.02%
PUT$ 6.5011/17/226$ 0.45$ 0.60$ 0.55165453.671.86%
CALL$ 8.0011/24/2213$ 0.45$ 0.75$ 0.8514101.401.72%
CALL$ 11.0012/01/2220$ 0.25$ 0.50$ 0.4054252.161.95%
CALL$ 7.0012/15/2234$ 1.45$ 1.55$ 1.552802014.001.75%
CALL$ 10.0012/15/2234$ 0.70$ 0.80$ 0.752,1409722.061.82%
PUT$ 7.0012/15/2234$ 1.45$ 1.60$ 1.55150632.381.75%
CALL$ 9.0004/20/23160$ 1.55$ 1.95$ 8.78204653.141.29%
Last Updated: Thu, 10 Nov 2022 23:22 EST

Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Tue, 14 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.